Hengrui Medicine has recently announced that its drug candidate, Riconazole injection, in combination with Adebelimab injection and chemotherapy, has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of gastric cancer or adenocarcinoma of the gastroesophageal junction. On the same day, Dizeal Pharmaceutical also announced that its investigational product, DZD8586, has been granted Fast Track Designation by the FDA. Lately, there has been a surge in announcements regarding Chinese innovative drugs expanding globally, marked by significant advancements in overseas clinical trials, a peak in outbound licensing deals, and the rapid realization of their innovation value. Industry experts note that the level of innovation in Chinese drugs is consistently on the rise, gradually earning them international competitiveness and heralding a wave of global expansion.